Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q27693313)
Watch
English
Bispecific T-cell engagers for cancer immunotherapy
scientific article
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
PubMed
review article
1 reference
stated in
Europe PubMed Central
title
Bispecific T-cell engagers for cancer immunotherapy
(English)
1 reference
stated in
PubMed
main subject
immunotherapy
1 reference
based on heuristic
inferred from title
author name string
Huehls AM
series ordinal
1
1 reference
stated in
PubMed
Coupet TA
series ordinal
2
1 reference
stated in
PubMed
Sentman CL
series ordinal
3
1 reference
stated in
PubMed
publication date
March 2015
1 reference
stated in
PubMed
published in
Immunology & Cell Biology
1 reference
stated in
PubMed
volume
93
1 reference
stated in
PubMed
page(s)
290-6
1 reference
stated in
PubMed
issue
3
1 reference
stated in
PubMed
cites work
Antigen-Specific T-Cell Activation Independently of the MHC: Chimeric Antigen Receptor-Redirected T Cells
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445461
retrieved
20 March 2017
Highly efficient elimination of colorectal tumor-initiating cells by an EpCAM/CD3-bispecific antibody engaging human T cells
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445461
retrieved
20 March 2017
Bispecific antibodies for cancer therapy: the light at the end of the tunnel?
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445461
retrieved
20 March 2017
The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445461
retrieved
20 March 2017
Bispecific T-cell engaging antibodies for cancer therapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445461
retrieved
20 March 2017
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445461
retrieved
20 March 2017
Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445461
retrieved
20 March 2017
Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445461
retrieved
29 September 2017
Antibody-modified T cells: CARs take the front seat for hematologic malignancies
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445461
retrieved
29 September 2017
Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445461
retrieved
29 September 2017
Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445461
retrieved
29 September 2017
Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445461
retrieved
29 September 2017
A novel bispecific single-chain antibody for ADAM17 and CD3 induces T-cell-mediated lysis of prostate cancer cells
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445461
retrieved
29 September 2017
Redirected lysis of human melanoma cells by a MCSP/CD3-bispecific BiTE antibody that engages patient-derived T cells
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445461
retrieved
29 September 2017
Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445461
retrieved
29 September 2017
T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445461
retrieved
29 September 2017
Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445461
retrieved
29 September 2017
Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445461
retrieved
29 September 2017
Multiple mechanisms are responsible for transactivation of the epidermal growth factor receptor in mammary epithelial cells.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445461
retrieved
29 September 2017
Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445461
retrieved
29 September 2017
Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445461
retrieved
29 September 2017
Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445461
retrieved
29 September 2017
MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445461
retrieved
29 September 2017
T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445461
retrieved
29 September 2017
Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445461
retrieved
29 September 2017
Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445461
retrieved
29 September 2017
Formatting antibody fragments to mediate specific therapeutic functions
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445461
retrieved
29 September 2017
A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445461
retrieved
29 September 2017
Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445461
retrieved
29 September 2017
CD3 x CD19 bispecific antibodies and CD28 costimulation for locoregional treatment of low-malignancy non-Hodgkin's lymphoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445461
retrieved
29 September 2017
A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445461
retrieved
29 September 2017
Hybrid antibodies can target sites for attack by T cells
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445461
retrieved
29 September 2017
Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445461
retrieved
2 June 2018
The role of T cell activation in anti-CD3 x antitumor bispecific antibody therapy.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445461
retrieved
2 June 2018
Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FICB.2014.93
retrieved
21 January 2018
Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FICB.2014.93
retrieved
21 January 2018
Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigens.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FICB.2014.93
retrieved
21 January 2018
Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FICB.2014.93
retrieved
21 January 2018
Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FICB.2014.93
retrieved
21 January 2018
Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FICB.2014.93
retrieved
21 January 2018
A Theoretical Model of γ-Globulin Catabolism
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1038%2FICB.2014.93
retrieved
21 January 2018
Novel humanized and highly efficient bispecific antibodies mediate killing of prostate stem cell antigen-expressing tumor cells by CD8+ and CD4+ T cells
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/25367186
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/25367186
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/25367186
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Lysis of cancer cells by autologous T cells in breast cancer pleural effusates treated with anti-EpCAM BiTE antibody MT110
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/25367186
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/25367186
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Overview of prostate-specific membrane antigen
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/25367186
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/25367186
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Identifiers
DOI
10.1038/ICB.2014.93
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
1216002
OpenCitations bibliographic resource ID
1216002
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
1216002
PMCID
4445461
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
1216002
PubMed ID
25367186
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
1216002
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
